Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers

Podobne zapisy

• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  od: Uemura, Takehiro, i wsp.
  Wydane: (2017)
• Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
  od: Leprieur, Etienne Giroux, i wsp.
  Wydane: (2016)
• Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning
  od: Klempner, Samuel J., i wsp.
  Wydane: (2015)
• First-line treatment of advanced ALK-positive non-small-cell lung cancer
  od: Gandhi, Shipra, i wsp.
  Wydane: (2015)
• Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
  od: van der Wekken, Anthonie J., i wsp.
  Wydane: (2018)